EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Orphan Drug Development for Rare Diseases: Therapeutic Challenges, Translational Strategies, and Global Health Equity

Olabisi Promise Lawal, Enibokun Theresa Orobator, Sokoya Itunuoluwa Dorcas, Victor Chiedozie Ezeamii, Evelyn Foster-Pagaebi, Muhammad Attahiru

Journal of Life Science and Public Health · 2025

DOI: 10.69739/jlsph.v1i1.538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Life Science and Public Health, 2025. Verfasst von Olabisi Promise Lawal und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Orphan drug development for rare diseases presents unique challenges that require targeted scientific, economic, and policy-based responses. With over 300 million individuals globally affected by rare diseases, the need for effective therapies is urgent. However, development is hindered by limited biological understanding, small patient populations, and difficulties in clinical trial recruitment. High research and development costs and inconsistent market incentives further discourage investment, especially in low- and middle-income countries (LMICs). Ethical concerns around access and affordability deepen disparities. To address these issues, legislative measures such as the U.S. Orphan Drug Act and similar policies in the EU and Japan offer benefits like market exclusivity and expedited regulatory review. Advances in genomic sequencing, artificial intelligence, and real-world data are enhancing diagnostics and drug discovery. Collaborative research models, adaptive trial designs, and decentralized clinical trials improve feasibility and inclusivity. Equity-driven frameworks such as tiered pricing and support for local manufacturing are critical to expanding access in LMICs.This article examines the interconnected challenges of orphan drug development and outlines evidence-based strategies to improve therapeutic innovation and global access. A coordinated, multisectoral effort is essential to ensure that the benefits of precision medicine and translational research extend beyond high-income countries and contribute to global health equity.

Zitieren

APA

Lawal, O. P., Orobator, E. T., Dorcas, S. I., Ezeamii, V. C., Foster-Pagaebi, E., & Attahiru, M. (2025). Orphan Drug Development for Rare Diseases: Therapeutic Challenges, Translational Strategies, and Global Health Equity. Journal of Life Science and Public Health. https://doi.org/10.69739/jlsph.v1i1.538

Vancouver

Lawal OP, Orobator ET, Dorcas SI, Ezeamii VC, Foster-Pagaebi E, Attahiru M. Orphan Drug Development for Rare Diseases: Therapeutic Challenges, Translational Strategies, and Global Health Equity. Journal of Life Science and Public Health. 2025. doi:10.69739/jlsph.v1i1.538

BibTeX
@article{Lawal2025,
  author = {Lawal, Olabisi Promise and Orobator, Enibokun Theresa and Dorcas, Sokoya Itunuoluwa and Ezeamii, Victor Chiedozie and Foster-Pagaebi, Evelyn and Attahiru, Muhammad},
  title = {Orphan Drug Development for Rare Diseases: Therapeutic Challenges, Translational Strategies, and Global Health Equity},
  journal = {Journal of Life Science and Public Health},
  year = {2025},
  doi = {10.69739/jlsph.v1i1.538}
}
Kostenlos starten →